Advances in global biotechnology and local resources to treat malaria.

Ann M. Campagna, Mrinal M Patnaik

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The global campaign toward malaria eradication has received a tremendous boost with the addition of artemisinin compounds to the therapeutic armament. Artemisinin drugs are now being recommended in combination with existing antimalarials, a pairing often referred to as artemisinin-based combination therapy (ACT). The World Health Organization considers ACT first-line treatment for uncomplicated malaria in endemic regions. In the United States, ACT is not currently FDA-approved. The Walter Reed Army Institute of Research, however, is studying its use and developing artemisinin compounds for the treatment of severe malaria. Artesunate, one of the artemisinin derivatives, is available to eligible patients in the United States free of charge. The drug is stocked at the CDC headquarters, as well as at 7 of the 20 quarantine stations.

Original languageEnglish (US)
Pages (from-to)44-45
Number of pages2
JournalMinnesota medicine.
Volume92
Issue number2
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Biotechnology
Malaria
Isolation Hospitals
Therapeutics
Antimalarials
Centers for Disease Control and Prevention (U.S.)
artemisinine
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in global biotechnology and local resources to treat malaria. / Campagna, Ann M.; Patnaik, Mrinal M.

In: Minnesota medicine., Vol. 92, No. 2, 02.2009, p. 44-45.

Research output: Contribution to journalArticle

@article{4baf7e46746e40a7bbc71b9be924a791,
title = "Advances in global biotechnology and local resources to treat malaria.",
abstract = "The global campaign toward malaria eradication has received a tremendous boost with the addition of artemisinin compounds to the therapeutic armament. Artemisinin drugs are now being recommended in combination with existing antimalarials, a pairing often referred to as artemisinin-based combination therapy (ACT). The World Health Organization considers ACT first-line treatment for uncomplicated malaria in endemic regions. In the United States, ACT is not currently FDA-approved. The Walter Reed Army Institute of Research, however, is studying its use and developing artemisinin compounds for the treatment of severe malaria. Artesunate, one of the artemisinin derivatives, is available to eligible patients in the United States free of charge. The drug is stocked at the CDC headquarters, as well as at 7 of the 20 quarantine stations.",
author = "Campagna, {Ann M.} and Patnaik, {Mrinal M}",
year = "2009",
month = "2",
language = "English (US)",
volume = "92",
pages = "44--45",
journal = "Minnesota medicine.",
issn = "0026-556X",
publisher = "Minnesota Medical Association",
number = "2",

}

TY - JOUR

T1 - Advances in global biotechnology and local resources to treat malaria.

AU - Campagna, Ann M.

AU - Patnaik, Mrinal M

PY - 2009/2

Y1 - 2009/2

N2 - The global campaign toward malaria eradication has received a tremendous boost with the addition of artemisinin compounds to the therapeutic armament. Artemisinin drugs are now being recommended in combination with existing antimalarials, a pairing often referred to as artemisinin-based combination therapy (ACT). The World Health Organization considers ACT first-line treatment for uncomplicated malaria in endemic regions. In the United States, ACT is not currently FDA-approved. The Walter Reed Army Institute of Research, however, is studying its use and developing artemisinin compounds for the treatment of severe malaria. Artesunate, one of the artemisinin derivatives, is available to eligible patients in the United States free of charge. The drug is stocked at the CDC headquarters, as well as at 7 of the 20 quarantine stations.

AB - The global campaign toward malaria eradication has received a tremendous boost with the addition of artemisinin compounds to the therapeutic armament. Artemisinin drugs are now being recommended in combination with existing antimalarials, a pairing often referred to as artemisinin-based combination therapy (ACT). The World Health Organization considers ACT first-line treatment for uncomplicated malaria in endemic regions. In the United States, ACT is not currently FDA-approved. The Walter Reed Army Institute of Research, however, is studying its use and developing artemisinin compounds for the treatment of severe malaria. Artesunate, one of the artemisinin derivatives, is available to eligible patients in the United States free of charge. The drug is stocked at the CDC headquarters, as well as at 7 of the 20 quarantine stations.

UR - http://www.scopus.com/inward/record.url?scp=64749106850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749106850&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 44

EP - 45

JO - Minnesota medicine.

JF - Minnesota medicine.

SN - 0026-556X

IS - 2

ER -